Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 6;12(1):117.
doi: 10.3390/microorganisms12010117.

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies

Giovanni Mori  1   2 , Sara Diotallevi  3 , Francesca Farina  4 , Riccardo Lolatto  3 , Laura Galli  3 , Matteo Chiurlo  1   3 , Andrea Acerbis  1   4 , Elisabetta Xue  4   5 , Daniela Clerici  4 , Sara Mastaglio  4 , Maria Teresa Lupo Stanghellini  4 , Marco Ripa  1   3 , Consuelo Corti  4 , Jacopo Peccatori  4 , Massimo Puoti  6   7 , Massimo Bernardi  4 , Antonella Castagna  1   3 , Fabio Ciceri  1   4 , Raffaella Greco  4 , Chiara Oltolini  3   6
Affiliations
Review

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies

Giovanni Mori et al. Microorganisms. .

Abstract

Invasive fungal diseases (IFDs) still represent a relevant cause of mortality in patients affected by hematological malignancies, especially acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing remission induction chemotherapy, and in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Mold-active antifungal prophylaxis (MAP) has been established as a standard of care. However, breakthrough IFDs (b-IFDs) have emerged as a significant issue, particularly invasive aspergillosis and non-Aspergillus invasive mold diseases. Here, we perform a narrative review, discussing the major advances of the last decade on prophylaxis, the diagnosis of and the treatment of IFDs in patients with high-risk neutropenic fever undergoing remission induction chemotherapy for AML/MDS and allo-HSCT. Then, we present our single-center retrospective experience on b-IFDs in 184 AML/MDS patients undergoing high-dose chemotherapy while receiving posaconazole (n = 153 induction treatments, n = 126 consolidation treatments, n = 60 salvage treatments). Six cases of probable/proven b-IFDs were recorded in six patients, with an overall incidence rate of 1.7% (6/339), which is in line with the literature focused on MAP with azoles. The incidence rates (IRs) of b-IFDs (95% confidence interval (95% CI), per 100 person years follow-up (PYFU)) were 5.04 (0.47, 14.45) in induction (n = 2), 3.25 (0.0013, 12.76) in consolidation (n = 1) and 18.38 (3.46, 45.06) in salvage chemotherapy (n = 3). Finally, we highlight the current challenges in the field of b-IFDs; these include the improvement of diagnoses, the expanding treatment landscape of AML with molecular targeted drugs (and related drug-drug interactions with azoles), evolving transplantation techniques (and their related impacts on IFDs' risk stratification), and new antifungals and their features (rezafungin and olorofim).

Keywords: acute leukaemia; allogeneic hematopoietic stem cell transplantation; antifungal prophylaxis; invasive fungal diseases; neutropenic fever.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Pagano L., Busca A., Candoni A., Cattaneo C., Cesaro S., Fanci R., Nadali G., Potenza L., Russo D., Tumbarello M., et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31:17–29. doi: 10.1016/j.blre.2016.09.002. - DOI - PubMed
    1. Posteraro B., De Carolis E., Criscuolo M., Ballanti S., De Angelis G., Del Principe M.I., Delia M., Fracchiolla N., Marchesi F., Nadali G., et al. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. Mycoses. 2020;63:900–910. doi: 10.1111/myc.13130. - DOI - PubMed
    1. Souza L., Nouér S.A., Morales H., Simões B., Solza C., Queiroz-Telles F., Nucci M. Epidemiology of invasive fungal disease in haematologic patients. Mycoses. 2021;64:252–256. doi: 10.1111/myc.13205. - DOI - PubMed
    1. Bergamasco M.D., Pereira C.A.P., Arrais-Rodrigues C., Ferreira D.B., Baiocchi O., Kerbauy F., Nucci M., Colombo A.L. Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach. J. Fungi. 2021;7:588. doi: 10.3390/jof7080588. - DOI - PMC - PubMed
    1. Puerta-Alcalde P., Garcia-Vidal C. Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation. J. Fungi. 2021;7:848. doi: 10.3390/jof7100848. - DOI - PMC - PubMed